FDAsafety guidance77% confidence
FDA AP — NDA219627
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Methylprednisolone; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA219627. Sponsor: BAYER HEALTHCARE PHARMS. Submission status: AP. Submission type: ORIG. Review priority: STANDARD.
Supporting Context
- Therapeutic area
- Immunology · Corticosteroid
- Sub-indication
- General
Related signal: FDA Grants AP Status for Methylprednisolone ANDA210985 by Ingenus Pharms